Scienture gets exclusive US rights to commercialize REZENOPY naloxone nasal spray from Kindeva

Scienture Holdings, Inc.

Exclusive 10-year US license to commercialize REZENOPY (naloxone HCl 10mg) from Kindeva; term expires 10 yrs from first commercial sale.
Supply price $9.20/unit; profit-sharing 10% of net sales (8% upon generic entry); additional 5% until $12.8M NDA cost recovered.
Milestone payments up to $10M based on net sales targets; $1M upfront milestones due in stages.
Minimum order: 3 batches of 450,000 units/year from 2027 or $1.242M/year; $189M total naloxone market (IQVIA MAT Dec 2024).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.